PDIA3 as a potential bridge between immunogenic cell death and autoreactivity

Jonathan G. Pol; Céleste Plantureux; María Pérez-Lanzón; Guido Kroemer

doi:10.1080/2162402X.2022.2130558

PDIA3 as a potential bridge between immunogenic cell death and autoreactivity

Jonathan G. Pol, Céleste Plantureux, María Pérez-Lanzón, Guido Kroemer

Résultats de recherche: Contribution à un journal › Editorial

3 Citations (Scopus)

langue originale	Anglais
Numéro d'article	2130558
journal	OncoImmunology
Volume	11
Numéro de publication	1
Les DOIs	https://doi.org/10.1080/2162402X.2022.2130558
état	Publié - 1 janv. 2022
Modification externe	Oui

Accès au document

10.1080/2162402X.2022.2130558

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{1820de66a17f4939bf8a17e5ab8b655f,

title = "PDIA3 as a potential bridge between immunogenic cell death and autoreactivity",

author = "Pol, {Jonathan G.} and C{\'e}leste Plantureux and Mar{\'i}a P{\'e}rez-Lanz{\'o}n and Guido Kroemer",

note = "Funding Information: J.G.P is supported by the SIRIC Cancer Research and Personalized Medicine (CARPEM); Multi-Organism Institute (ITMO) Aviesan Cancer (National Alliance for Life Sciences and Health), Institut National du Cancer (INCa), and Fondation pour la Recherche M{\'e}dicale (FRM). G.K. is supported by the Ligue contre le Cancer ({\'e}quipe labellis{\'e}e); Agence National de la Recherche (ANR)–Projets blancs; AMMICa US23/CNRS UMS3655; Association pour la recherche sur le cancer (ARC); Association “Ruban Rose”; Canc{\'e}rop{\^o}le Ile-de-France; Fondation pour la Recherche M{\'e}dicale (FRM); a donation by Elior; Equipex Onco-Pheno-Screen; European Joint Programme on Rare Diseases (EJPRD); Gustave Roussy Odyssea, the European Union Horizon 2020 Projects Oncobiome and Crimson; Fondation Carrefour; Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LabEx Immuno-Oncology (ANR-18-IDEX-0001); the Leducq Foundation; the RHU Torino Lumi{\`e}re; Seerave Foundation; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and SIRIC Cancer Research and Personalized Medicine (CARPEM). This study contributes to the IdEx Universit{\'e} de Paris ANR-18-IDEX-0001. Funding Information: J.G.P is supported by the SIRIC Cancer Research and Personalized Medicine (CARPEM); Multi-Organism Institute (ITMO) Aviesan Cancer (National Alliance for Life Sciences and Health), Institut National du Cancer (INCa), and Fondation pour la Recherche M{\'e}dicale (FRM). G.K. is supported by the Ligue contre le Cancer ({\'e}quipe labellis{\'e}e); Agence National de la Recherche (ANR) – Projets blancs; AMMICa US23/CNRS UMS3655; Association pour la recherche sur le cancer (ARC); Association “Ruban Rose”; Canc{\'e}rop{\^o}le Ile-de-France; Fondation pour la Recherche M{\'e}dicale (FRM); a donation by Elior; Equipex Onco-Pheno-Screen; European Joint Programme on Rare Diseases (EJPRD); Gustave Roussy Odyssea, the European Union Horizon 2020 Projects Oncobiome and Crimson; Fondation Carrefour; Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LabEx Immuno-Oncology (ANR-18-IDEX-0001); the Leducq Foundation; the RHU Torino Lumi{\`e}re; Seerave Foundation; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and SIRIC Cancer Research and Personalized Medicine (CARPEM). This study contributes to the IdEx Universit{\'e} de Paris ANR-18-IDEX-0001. ",

year = "2022",

month = jan,

day = "1",

doi = "10.1080/2162402X.2022.2130558",

language = "English",

volume = "11",

journal = "OncoImmunology",

issn = "2162-4011",

number = "1",

}

TY - JOUR

T1 - PDIA3 as a potential bridge between immunogenic cell death and autoreactivity

AU - Pol, Jonathan G.

AU - Plantureux, Céleste

AU - Pérez-Lanzón, María

AU - Kroemer, Guido

N1 - Funding Information: J.G.P is supported by the SIRIC Cancer Research and Personalized Medicine (CARPEM); Multi-Organism Institute (ITMO) Aviesan Cancer (National Alliance for Life Sciences and Health), Institut National du Cancer (INCa), and Fondation pour la Recherche Médicale (FRM). G.K. is supported by the Ligue contre le Cancer (équipe labellisée); Agence National de la Recherche (ANR)–Projets blancs; AMMICa US23/CNRS UMS3655; Association pour la recherche sur le cancer (ARC); Association “Ruban Rose”; Cancéropôle Ile-de-France; Fondation pour la Recherche Médicale (FRM); a donation by Elior; Equipex Onco-Pheno-Screen; European Joint Programme on Rare Diseases (EJPRD); Gustave Roussy Odyssea, the European Union Horizon 2020 Projects Oncobiome and Crimson; Fondation Carrefour; Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LabEx Immuno-Oncology (ANR-18-IDEX-0001); the Leducq Foundation; the RHU Torino Lumière; Seerave Foundation; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and SIRIC Cancer Research and Personalized Medicine (CARPEM). This study contributes to the IdEx Université de Paris ANR-18-IDEX-0001. Funding Information: J.G.P is supported by the SIRIC Cancer Research and Personalized Medicine (CARPEM); Multi-Organism Institute (ITMO) Aviesan Cancer (National Alliance for Life Sciences and Health), Institut National du Cancer (INCa), and Fondation pour la Recherche Médicale (FRM). G.K. is supported by the Ligue contre le Cancer (équipe labellisée); Agence National de la Recherche (ANR) – Projets blancs; AMMICa US23/CNRS UMS3655; Association pour la recherche sur le cancer (ARC); Association “Ruban Rose”; Cancéropôle Ile-de-France; Fondation pour la Recherche Médicale (FRM); a donation by Elior; Equipex Onco-Pheno-Screen; European Joint Programme on Rare Diseases (EJPRD); Gustave Roussy Odyssea, the European Union Horizon 2020 Projects Oncobiome and Crimson; Fondation Carrefour; Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LabEx Immuno-Oncology (ANR-18-IDEX-0001); the Leducq Foundation; the RHU Torino Lumière; Seerave Foundation; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and SIRIC Cancer Research and Personalized Medicine (CARPEM). This study contributes to the IdEx Université de Paris ANR-18-IDEX-0001.

PY - 2022/1/1

Y1 - 2022/1/1

UR - http://www.scopus.com/inward/record.url?scp=85139230712&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2022.2130558

DO - 10.1080/2162402X.2022.2130558

M3 - Editorial

C2 - 36211809

AN - SCOPUS:85139230712

SN - 2162-4011

VL - 11

JO - OncoImmunology

JF - OncoImmunology

IS - 1

M1 - 2130558

ER -